An international study analyzed the use of pentoxifylline in treating severe alcohol-associated hepatitis with acute kidney injury (AKI) in 525 hospitalized patients. The results showed no significant difference in survival between patients who received pentoxifylline and those who didn't. The study emphasized the need for more effective therapies for severe alcohol-associated hepatitis, particularly in patients with kidney complications.

Source: eGastroenterology